Key result
Two iPSC lines generated from patients with MYBPC3-associated HCM display normal morphology and pluripotency.
Why the study?
Mutations in MYBPC3 are a leading cause of hypertrophic cardiomyopathy, and patient-specific stem cell lines were needed to enable disease modeling, mechanistic studies, and therapeutic investigations.
The generation of these patient-specific iPSC lines provides a valuable platform for modeling MYBPC3-associated hypertrophic cardiomyopathy and enabling mechanistic and therapeutic studies.
Answers are grounded in this paper and cite their sources.
Should not yet change HCM practice; extends patient-specific iPSC platform for MYBPC3 mechanistic and therapeutic studies.
Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder characterized by left ventricular hypertrophy and contractile dysfunction. Mutations in sarcomeric genes, particularly cardiac myosin-binding protein C ( MYBPC3 ), are a leading cause of HCM. Here, we generated two induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells of patients carrying distinct MYBPC3 mutations (c.2490dupT and c.1800delA). Both lines displayed normal morphology, stable karyotypes, robust expression of pluripotency markers, and trilineage differentiation potential. These patient-specific iPSC lines provide a valuable platform for modeling MYBPC3-associated HCM and enable mechanistic and therapeutic studies of inherited cardiac disease
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied Hypertrophic cardiomyopathy (n=2). Generation of induced pluripotent stem cell (iPSC) lines was evaluated on iPSC line characterization (morphology, karyotype, pluripotency markers, trilineage differentiation). Two induced pluripotent stem cell lines from patients with MYBPC3-associated hypertrophic cardiomyopathy were successfully generated, displaying normal morphology and pluripotency.
Synapse has enriched 10 related papers. Consider them for comparative context: